hypercholesterolaemia and ASCVD
Cardiovascular · 2023–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| inclisiran Treatment of hypercholesterolaemia and atherosclerotic cardiovascular disease (ASCVD) in patients with additional cardiovascular risk factors who are unable to… | May 2023 | Not recommended | 3 individuals Familial Hypercholesterolaemia Australasia Network · Heart Foundation |
Who spoke
Familial Hypercholesterolaemia Australasia Network · Heart Foundation
What the PBS pays
$38M in government benefit over 2024–25, across 20,827 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| inclisiran | $38.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.